Most Read Articles
Stephen Padilla, 12 Dec 2019
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Christina Lau, 14 Oct 2019

Denosumab can be of benefit to patients with unresectable giant cell tumour of bone (GCTB) and those who are likely to experience significant morbidity after surgical resection of GCTB.

10 Mar 2017
The addition of pravastatin to standard chemotherapy does not improve outcomes in patients with small-cell lung cancer (SCLC), results of a study have shown.
Tristan Manalac, 03 Dec 2019
Incorporating basic tumour characteristics, such as hormone receptor status and tumour origin, improves the power of the cell-loss metric to predict response to treatment, according to a new study presented at the recently concluded 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).

BMI at younger vs older age strongly predicts pancreatic cancer

10 Nov 2019

A higher body mass index (BMI) appears to translate to an increased risk of developing pancreatic cancer in men and women aged <50 years but not in those who are older, a study has found.

The study used data from the Cancer Prevention Study-II in 1982 and included 963,317 adults (55.94 percent female) aged 30–89 years at baseline. The average age at BMI assessment was 56 years.

During follow-up through 2014, 8,354 participants died of pancreatic cancer. Proportional hazards regression showed that the risk of pancreatic cancer declined steadily with age at BMI assessment. Hazard ratios (HRs) per 5 BMI-units ranged from 1.25 (95 percent confidence interval [CI], 1.18–1.33) in those aged 30–49 years to 1.13 (95 percent CI, 1.02–1.26) in those aged 70–89 years (p-trend=0.005).

Researchers noted that based on an HR estimate of 1.25 per 5 BMI-units at age 45 years, 28 percent of pancreatic cancer deaths in the US among individuals born from 1970–1974 will be attributable to BMI >25 kg/m2. This number is nearly twice the estimated 15 percent pancreatic cancer deaths among men and women born in the 1930s, a birth cohort with much lower BMI in middle age.

The present data suggest that BMI measured only at older ages is unlikely to fully capture the impact of high BMI earlier in life on the risk of pancreatic cancer, the researchers said. They emphasized the importance of preventing weight gain before middle age, at both individual and community-level, for reducing rates of this highly fatal cancer in the 2030s and beyond.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 12 Dec 2019
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Christina Lau, 14 Oct 2019

Denosumab can be of benefit to patients with unresectable giant cell tumour of bone (GCTB) and those who are likely to experience significant morbidity after surgical resection of GCTB.

10 Mar 2017
The addition of pravastatin to standard chemotherapy does not improve outcomes in patients with small-cell lung cancer (SCLC), results of a study have shown.
Tristan Manalac, 03 Dec 2019
Incorporating basic tumour characteristics, such as hormone receptor status and tumour origin, improves the power of the cell-loss metric to predict response to treatment, according to a new study presented at the recently concluded 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).